Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2022, 4(6); doi: 10.25236/FMSR.2022.040606.

Investigation of the Role of TCM in the Treatment of Hepatic Carcinoma Based on JAK/STAT Signaling Pathway


Yiyi Song1, Xuanli Li1, Jie Chen2

Corresponding Author:
Yiyi Song

1Shaanxi University of Chinese Medicine, China

2Shaanxi Hospital of Traditional Chinese Medicine, China


JAK/STAT signaling pathway is one of the classical signaling pathways. Numerous studies have shown that this signaling pathway provides a suitable microenvironment for tumors by inducing inflammatory responses, and it is closely related to tumorigenesis, development and invasion. Given the fact that targeted therapies for hepatic carcinoma have limited efficacy, perhaps this pathway may serve as an entry point for new targeted therapies for hepatic carcinoma in the future. Due to the above considerations, in recent years, there have been many articles reporting that TCM monomers and compound preparations act on this pathway and have prominent effects in the clinical treatment of hepatic carcinoma with few side effects. This paper focuses on the systematic discussion of Chinese herbal medicines acting on this mechanism, aiming to provide more ideas and basis for the treatment of hepatic carcinoma in Chinese medicine.


JAK/STAT signaling pathway; hepatic carcinoma; herbal monomer; herbal compound; treatment of hepatic carcinoma Introduction

Cite This Paper

Yiyi Song, Xuanli Li, Jie Chen. Investigation of the Role of TCM in the Treatment of Hepatic Carcinoma Based on JAK/STAT Signaling Pathway. Frontiers in Medical Science Research (2022) Vol. 4, Issue 6: 32-37. https://doi.org/10.25236/FMSR.2022.040606.


[1] Ferlay J, Soerjomataram I, Parkin DM et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. int J Cancer136: E359-E386.

[2] Kirstein MM, Wirth TC. Multimodale Therapie des hepatozellulären Karzinoms [Multimodal treatment of hepatocellular carcinoma]. Internist (Berl). 2020 Feb;61(2):164-169. German. doi: 10.1007/s00108-019-00722-x. PMID: 31919533.

[3] Jiang Z-Y, Hua H-Q. Research progress on molecular mechanism of Chinese medicine against hepatic carcinoma [J]. Chinese Journal of Traditional Chinese Medicine,2009, 34(10): 1310-1313.

[4] Brodsky SV, Mendelev N, Melamed M, et al. Vasclar density and VEGF expression in hepatic lesions [J]. J Gastrointestin Liver Dis, 2007, 16(4):373-377

[5] SEIJI MABUCHI, HIROMASA KURODA, RYOKO TAKAHASHI, et al. The PI3K/Akt /mTOR pathway as a therapeutic target in ovarian cancer [J]. Gynecologic Oncology,2015, 137(1): 173-179

[6] Heng j, Li C, Wu X, et a1. Astrocyte elevated gene I1 (AEG I1) shRNA sensitizes Huaier polysaccharide (Hand)-induced anti-metastatic potency via inactivating downstream Pl 3K/Akt pathway as well as augmenting cell-mediated immune response. Tumour Biol 2014; 35: 421 9-24.

[7] Schoppy DW, Ragland RL, Gilad O, et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR [J]. J Clin Invest,2012, 122(1): 241-252

[8] Owen, Katie L et al. "JAK-STAT Signaling: a Double-Edged Sword of Immune Regulation and Cancer Progression." cancers vol. 11, 12 2002. 12 Dec. 2019, doi: 10.3390/cancers11122002

[9] Xiao Yuehong. Discussion on the TCM pathogenesis and prevention of primary hepatic carcinoma [J]. Chinese Journal of Basic Chinese Medicine, 201319(6): 617- 648.

[10] Ye LH, Cheng HB, Wu MH, Luo D, Zhang YH, Zhou ZY. Considerations on the characteristics of Chinese medicine pathogenesis in primary hepatic carcinoma [J]. Journal of Traditional Chinese Medicine,2010, 51(06): 557-559.

[11] Chen L Q, Liu G J. Research progress and perspectives on the relationship between STAT1 and tumors [J]. Chinese Journal of Cell Biology,2017, 39(12):1612-1618.

[12] Rawlings J S, Rosler K M, Harrison D A. The JAK/STAT signaling pathway [J]. J Cell Sci, 2004(117): 1281-1283

[13] Xin, Ping" JAK/STAT signaling pathways and their inhibitors in the role of disease. international Immuno pharmacology Vol. 80 (2020): 106210. doi. 10.1016/j.intimp.2020.106210

[14] KANG F B, WANG L, JIA H C, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelialto-mesenchymal B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelialto-mesenchymal transition via JAK2/STAT3/Slug signaling pathway [J]. Cancer Cell Int, 2015, (15): 45.

[15] He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168 [PMID: 21187858 DOI: 10.1038/cr.2010.183].

[16] Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-1128 [PMID: 16618406 DOI: 10.1053/j.gastro.2006.01.006] 

[17] Zhang B, Zhong DW, Wang QW, Miao XY, Dai WD, Liu C, Pan KH. [Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma]. Xibao Yu Fenzi Mianyixue Zazhi 2010; 26: 368-370, 373 [PMID: 20368117].

[18] Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011; 11: 506 [PMID: 22136659 DOI: 10.1186/1471-2407-11-506]

[19] Wu, Mengchao. The role, status and problems of Chinese medicine in the prevention and treatment of HCC [J]. Journal of Integrated Chinese and Western Medicine, 2003, 1(3): 163. 

[20] Long Y, Xiang Y, Tan YJ, Li N, Yang QY. Research progress of pharmacological effects and new dosage forms of baicalin [J]. Chinese herbal medicine,2019, 50(24): 6142-6148.

[21] Guo Y, Huo RJ, Yao JF. Effect of baicalin on STAT3 of JAK-STAT signaling pathway in SMMC-7721 hepatic carcinoma cells[J]. World Journal of Chinese Digestion,2011, 19(22): 2363-2367.

[22] Li Man, Zhang Lurong. Progress of research on the anti-inflammatory effect of the Chinese medicine Hedyotis diffusa [J]. Journal of Liaoning University of Traditional Chinese Medicine, 2021, 23(10): 164-167.

[23] Chang Xiu, Zhang Zhiyuan, Chen Fangrong. Exploration of the anti-inflammatory mechanism of Hedyotis diffusa [J]. Journal of Gannan Medical College, 1980, 1(1): 1 -13

[24] Sun Chao, Wu Mingjie et al. Mechanism of apoptosis in hepatic carcinoma cells induced by 2-hydroxy-3-methylanthraquinone, an active ingredient of Hedyotis diffusa, through IL-6/STAT3 signaling pathway [J]. Chinese Journal of Traditional Chinese Medicine,2018 33 (12): 5346-5350.

[25] LIU Z, CAO G, CONG X D. Research progress on chemical compositions and quality control of Verbena officinalis L. [J]. Asia-Pacific Tradit Med (Asia-Pacific Traditional Medicine),2011, 7 (10): 186- 188.

[26] Li YM, Li XJ. Effects of total flavonoids of Verbena officinalis on the levels of IL-6, JAK2 and STAT3 in hepatic carcinoma (HepG-2) cells [J]. Journal of Henan University of Science and Technology (Medical Edition), 2017, 35(03): 169-171.

[27] Editorial Board of the Chinese Academy of Sciences. Flora of China, Volume 40 [S]. Editorial Board of the Chinese Flora of the Chinese Academy of Sciences. Flora of China, Volume 40 [S].

[28] National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (Part I) [M]. Beijing: China Medical Science and Technology Publishing House,2015: 203. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (Part I) [M]. Beijing: China Medical Science and Technology Publishing House,2015: 203.

[29] Zhao Junyan, Zheng Yanmin, Zhao Hongyan, Yao Shukun. Effects of bittersweet and oxymatrine on the proliferation and apoptosis of hepatic carcinoma cells and JAK-STAT signaling pathway [J]. Chinese Pharmacology and Clinic, 2008(04): 18-20.

[30] ANAND P, KUNNUMAKKARA A B, NEWMAN R A, et al. Bioavailability of curcumin: problems and promises [J]. Mol Pharm,2007, 4(6): 807 - 818.

[31] Wang B, Pan Z Y, Yan Z C, Liu D Y, Lan L, Wang C, Jiang D. Effect of curcumin on the proliferation and expression of stem cell markers in human hepatic carcinoma (HCC) cells SMCC-7721 and its mechanism [J]. Hebei TCM,2016, 38(12): 1778-1783.

[32] Zhao Qiang, Meng Fanjing, Liu Anxi. Research progress of Chan Su [J]. Chinese herbal medicine, 2004, 35(10): Annex 4-Annex 7.

[33] Cheng G. H. Research on the quality of Chan Su and its pharmacological and clinical applications [J]. Chinese herbal medicine, 2001, 32(2): 90-92.

[34] Shen Fangxue. Study on the antihepatic carcinoma effect of huachansu and its components[D]. Shanghai University of Traditional Chinese Medicine.2019.

[35] Liu Yan. " Yiguan Decoction" in clinical application [J]. Clinical Research in Traditional Chinese Medicine, 2010, 2(2): 118 - 119

[36] Xu Jing, Lu Heqi et al. New Advances in Clinical and Experimental Research on Yiguan Decoction [J]. Hubei Journal of Traditional Chinese Medicine,2018, 48(7): 61 - 64.

[37] Xie B, Xie X, Rao B, Zhu WF, Liu HN. Effect of Yiguan Decoction on the expression of JAK1/STAT1 signaling pathway and its downstream apoptosis-related proteins in hepatic carcinoma (HCC) [J]. Chinese Journal of Experimental Formulary, 2017, 23(18): 100-104.

[38] Liu S.H., Li S.S., Hou Youjuan, Li B., Dong Y., Li B. A study of the ancient and modern literature on the clinical application of Biejiajian Pill from Jin Kui Essentials [J]. Chinese Journal of Experimental Formulary,2020, 26(06): 12-17.

[39] Wang JQ, Huang R. Progress in the study of the role of JAK-STAT signaling pathway in the development of hepatic carcinoma [J]. World Journal of Chinese Digestion,2013, 21(21): 2051-2056.

[40] Xiao Kunmin, Zhu Shijie et al. Effect of Modified Formula of Biejiajian Pill and its dismantled formula on hepatic carcinoma (H22) cells [J]. World Journal of Integrated Chinese and Western Medicine,2021, 16(08): 1379-1384.